Insights
UX111 under MHRA review: Sanfilippo gene therapy meets NICE HST
The MHRA has accepted Ultragenyx's Sanfilippo type A gene therapy for review, with NICE aligning its HST evaluation. A single-arm evidence package and a $3.95 million US price make it a test case.